News
Exicure’s subsidiary, GPCR Therapeutics doses 19th patient in its phase 2 study of GPC-100 in multiple myeloma: Redwood City, California Wednesday, April 16, 2025, 18:00 Hrs [IS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback